Cargando…
Cross‐reactive cellular, but not humoral, immunity is detected between OC43 and SARS‐CoV‐2 NPs in people not infected with SARS‐CoV‐2: Possible role of cT(FH) cells
Multiple questions about SARS‐CoV‐2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS‐CoV‐2‐unexposed individuals, can recognize and suppress COVID‐19, but this issue remains unclear. Here, we demo...
Autores principales: | García‐Jiménez, Álvaro Fernando, Cáceres‐Martell, Yaiza, Fernández‐Soto, Daniel, Martínez Fleta, Pedro, Casasnovas, José M., Sánchez‐Madrid, Francisco, Frade, José Miguel Rodríguez, Valés‐Gómez, Mar, Reyburn, Hugh T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088540/ https://www.ncbi.nlm.nih.gov/pubmed/35384035 http://dx.doi.org/10.1002/JLB.4COVCRA0721-356RRR |
Ejemplares similares
-
Single‐reaction multi‐antigen serological test for comprehensive evaluation of SARS‐CoV‐2 patients by flow cytometry
por: Cáceres‐Martell, Yaiza, et al.
Publicado: (2021) -
Effective inhibition of HCoV-OC43 and SARS-CoV-2 by phytochemicals in vitro and in vivo.
por: Ojha, Durbadal, et al.
Publicado: (2023) -
Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022) -
Antiviral Peptides Delivered by Chitosan-Based Nanoparticles to Neutralize SARS-CoV-2 and HCoV-OC43
por: Mali, Avinash, et al.
Publicado: (2023) -
Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2
por: Schirtzinger, Erin E., et al.
Publicado: (2022)